CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218)

Authors: Sani Kizilbash, David Piccioni, Solmaz Sahebjam, John Villano, Kurt Jaeckle, Mary Welch, Xiao-Tang Kong, Matthias Holdhoff, Anita Lammers, Adam Remick, Joel Reid, Jacob Allred, John Port, Ian Lanza, Samuel McBrayer, Charles Kunos, Geoffrey Shapiro, Alex Adjei

Published: 2022-11-14

DOI: 10.1093/neuonc/noac209.288

Source: Full article

CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218)

Abstract